Across TCGA pan-cancer cohorts, RNU6-692P RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated RNU6-692P data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RNU6-692P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-692P expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

BLCA, UCEC, and STAD are the cancer types where RNU6-692P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	All	0.051	0.720	<.001	144	view →
UCEC	OS	Tertile	All	0.121	0.679	.012	54	view →
STAD	OS	Tertile	IV	0.075	0.496	.013	18	view →
ESCA	DFS	Tertile	II,III,IV	0.521	0.358	.037	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RNU6-692P tumor-vs-normal RNA expression · all RNU6-692P data types